Terumo Corporation (TSE:4543) today announced that Terumo Group Sustainability Policy has been established. In accordance, the sustainability priorities for the Group have been revised.
Under the group mission of "Contributing to Society through Healthcare", Terumo has continued to listen to the voices of patients, medical professionals, and stakeholders, to realize a sustainable society balanced with a sustainable growth of the Terumo Group. In 2018, Terumo determined the sustainability priorities, and the company has been making efforts to resolve healthcare issues, other social and environmental issues based on the priorities.
However, the environment surrounding healthcare and society has undergone rapid changes recently more than ever. The spread of a global pandemic such as COVID-19 and changes in diseases structure highlight the needs for a sustainable medical system. Also, the evolution of technology and rising environmental risks, such as climate change, are accelerating the paradigm shift of society as a whole. To resolve these complicated challenges, social demands for the proactive involvement of companies are increasing. With this background, Terumo has newly enacted the Terumo Group Sustainability Policy and at the same time revised the sustainability priorities. With this guideline, Terumo will work on sustainability activities from a long-term/management perspective.
Terumo considers "Realization of the group mission" as the goal of sustainability activities and "Resolving healthcare challenges" as the most important sustainability priority for the Group. With this in mind, Terumo will strive for the realization of a sustainable society and the sustainable growth of the company by creating social values through the "Advancement of healthcare" and the "Enhancement of patients' QOL" in our main business areas. In addition, we have set six sustainable priorities including "Pursuing total quality", "Promoting active participation of associates", "Reducing the environmental impact", and "Lives and human rights of associates/business partners" as the foundation supporting social value creation. While responding to various social demands, Terumo will build a strong business foundation through the Group's unique activities.
With regard to specific initiatives related to the sustainability priorities, we will continue to disclose information in our sustainability report and other corporate communication tools.
Going forward, we will continue to work proactively to solve medical, social, and environmental issues as a leading company in the healthcare industry and contribute to a healthy and bright future for all people while meeting the expectations of a wide range of our stakeholders.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Corporate Communication Dept., Terumo Corporation
Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.